Cytogenetic findings in 200 patients with multiple myeloma

doi:10.1016/0165-4608(94)00284-I

Cancer Genetics and Cytogenetics

Volume 82, Issue 1, 1 July 1995, Pages 41-49

https://doi.org/10.1016/0165-4608(94)00284-I Get rights and content

Abstract

Cytogenetic studies were performed on 200 consecutive patients with multiple myeloma and related disorders. Structurally or numerically abnormal clones were found in 63 patients (32%), including 8 of 45 untreated patients (18%), and 55 of 155 treated patients (35%). The abnormal karyotypes generally showed numerous numerical and structural aberrations and in some patients multiple abnormal clones. The most striking feature of patients with hyperdiploid karyotypes was the finding of consistent recurring trisomies for chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, cosegregating together in many cases. Monosomy for chromosome 13 was the most common chromosome loss, occurring in 18 abnormal patients (29%), while interstitial deletions involving band 13814 occurred in an additional 9 patients, indicating a loss of all or part of chromosome 13 in a high percentage of patients with abnormal karyotypes (43%). Structural aberrations of chromosome 1 were most frequent, occurring in 30 of 63 patients (48%), and involved almost equally the short and long arms. The single most frequent chromosome breakpoint involved band 14q32 and was found in 21 patients (33%), including 11 patients with a 14q+ chromosome, 8 with t(11;14)(q13;q32), and 2 with t(8;14)(q24;q32).

References (33)

P. Philip et al.
Chromosomes and survival in multiple myeloma: a banding study of 25 cases
Cancer Genet Cytogenet
(1980)
H. Van den Berghe et al.
High incidence of chromosome abnormalities in IgGA myeloma
Cancer Genet Cytogenet
(1984)
J. Gould et al.
Plasma cell karyotype in multiple myeloma
Blood
(1988)
R.E. Clark et al.
Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma
Eur J Cancer Clin Oncol
(1989)
H.J. Weh et al.
Karyotype in multiple myeloma and plasma cell leukemia
Eur J Cancer
(1993)
S. Misawa et al.
Prefixation treatment with ethidium bromide for high resolution banding analysis of chromosomes from cultured human bone marrow cells
Cancer Genet Cytogenet
(1986)
J.J. Yunis
New chromosome techniques in the study of human neoplasia
Hum Pathol
(1981)
H. Tsuchiya et al.
Correlated flow cytometric analysis of H-rap p21 and nuclear DNA in multiple myeloma
Blood
(1988)
R. Morgan et al.
Deletion of chromosome band 13814: a primary event in preleukemia and leukemia
Cancer Genet Cytogenet
(1985)
N.B. Atkin
Chromosome 1 aberrations in cancer
Cancer Genet Cytogenet
(1986)

E. Olah et al.

Abnormalities of chromosome 1 in relation to human malignant disease

Cancer Genet Cytogenet

(1989)

J. Whang-Peng et al.

Burkitt's lymphoma in AIDS: cytogentic study

Blood

(1984)

S.C. Raimondi et al.

Multiple telomeric association of a trisomic whole q arm of chromosome 1 in a child with acute lymphoblastic leukemia

Cancer Genet Cytogenet

(1987)

B.G.M. Durie

Cellular and molecular genetic features of myeloma and related disorders

Hematol Oncol Clin N Am

(1992)

S. Heim et al.

Chronic lymphoproliferative disorders

A.A. Sandberg

The Chromosomes in Human Cancer and Leukemia

Cited by (334)

Genomic profiling of multiple myeloma: New insights and modern technologies
2020, Best Practice and Research: Clinical Haematology
Advances in technologies for genomic profiling, primarily with next generation sequencing, have lead to a better understanding of the complex genomic landscape in multiple myeloma. Integrated analysis of whole genome, exome and transcriptome sequencing has lead to new insights on disease drivers including translocations, copy number alterations, somatic mutations, and altered gene expression. Disease progression in multiple myeloma is largely driven by structural variations including the traditional immunoglobulin heavy chain (IGH) translocations and hyperdiploidy which are early events in myelomagenesis as well as more complex events spanning over multiple chromosomes and involving amplifications and deletions. In this review, we will discuss recent insights on the genomic landscape of multiple myeloma and their implications for disease progression and personalized treatment. We will review how sequencing assays compare to current clinical methods and give an overview of modern technologies for interrogating genomic aberrations.
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism
2017, Cell Reports
Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by which it influences tumorigenesis. We show that rs6877329 G > C resides in a predicted enhancer element that physically interacts with the transcription start site of ELL2. The rs6877329-C risk allele is associated with reduced enhancer activity and lowered ELL2 expression. Since ELL2 is critical to the B cell differentiation process, reduced ELL2 expression is consistent with inherited genetic variation contributing to arrest of plasma cell development, facilitating MM clonal expansion. These data provide evidence for a biological mechanism underlying a hereditary risk of MM at 5q15.
Optimal strategy for obtaining routine chromosome analysis by using negative fractions of CD138 enriched plasma cells
2016, Cancer Genetics
Fluorescence in situ hybridization (FISH) is superior to routine chromosome analysis (RCA) in detecting important prognostic genetic abnormalities in plasma cell dyscrasia (PCD); however, its sensitivity is hampered due to paucity of plasma cells (PC) in whole bone marrow (BM). Studies showed that the abnormality detection rate in enriched plasma cells (EPC) is greater than unselected plasma cells (UPC), but purification techniques are limiting to only FISH when sample volumes are inadequate. Not performing RCA may compromise patient care since RCA is equally important for detecting non-PC related abnormalities when the diagnosis is undefined. To resolve this critical issue, we designed a study where an immuno-magnetic CD138 enriched positive selection was used for FISH while the negative fraction (NF) was used to retrieve other myeloid elements for RCA. Parallel FISH studies were performed using UPC and CD138 EPC, while karyotyping was achieved using whole BM and discarded myeloid elements from the NF. Results showed that the abnormality rate of EPC was doubled compared to UPC for FISH, and CA displayed 100% success rate using the NF. PCD related chromosome abnormalities were confined to whole BM while non-PCD related abnormalities were found in both whole BM and NF. Our results demonstrate the feasibility of using the NF for RCA.
Cytogenetic Alterations and Correlation with Age and Gender in Patients of Multiple Myeloma: A Study from a Tertiary Care Center in Eastern India
2024, South Asian Journal of Cancer
Prognostic Impact of 1q21 in NDMM
2023, SSRN
Comparison of laboratory methods for the detection of neoplastic plasma cells in plasma cell dyscrasias
2022, Journal of Clinical Pathology

View all citing articles on Scopus

^☆: This study was supported in part by USPHS Grant PO1 CA55819 from the National Cancer Institute.

¹: We thank E. L. Thomas, C. M. Swanson and G. Sammartino for expert technical assistance.

View full text

Original articleCytogenetic findings in 200 patients with multiple myeloma☆

Abstract

Cancer Genet Cytogenet

Cancer Genet Cytogenet

Blood

Eur J Cancer Clin Oncol

Eur J Cancer

Cancer Genet Cytogenet

Hum Pathol

Blood

Cancer Genet Cytogenet

Cancer Genet Cytogenet

Cancer Genet Cytogenet

Blood

Cancer Genet Cytogenet

Hematol Oncol Clin N Am

Chronic lymphoproliferative disorders

The Chromosomes in Human Cancer and Leukemia

Original article
Cytogenetic findings in 200 patients with multiple myeloma☆